Investment, Funding & Disinvestments

Moscow opened access to its MosMedAI platform to healthcare institutions across Russia in 2024, following a decree by Russian President Vladimir Putin.

Sun Pharma disclosed the development in an exchange filing, confirming that Organon stockholders had voted in favour of the proposals required to advance the proposed merger transaction.

Under the proposed agreement, argenx will pay US$77 per share in cash to acquire all outstanding shares of Forte Biosciences.

The new facility will manufacture rapid diagnostic tests used in several areas of healthcare, including the detection of infectious diseases and epidemics, drug screening and the identification of cancer biomarkers.

Milly Glass SEZ director Mohamed Rashid said the company expects to break ground by the end of August 2026 and begin producing amber pharmaceutical bottles by July 2027.

The financing forms part of Biovac’s expansion programme, which aims to increase the company’s annual manufacturing capacity to as many as 500 million vaccine doses.

The company plans to construct a new three-story, 145,000-square-foot facility for drug product manufacturing and packaging next to its existing operations.

The funding round also attracted investment from the Global Innovation Fund, Africa Health Ventures and other undisclosed investors.

The renewed work aims to complete the university’s 5,300-square-metre Laboratory Complex, a project that began in 2014 but stalled for several years.

Under the terms of the agreement, Lilly will pay US$6.75 per share in cash, representing a 40% premium over AtaiBeckley’s 30-day volume-weighted average share price.